Oyster Point Pharma Finds $22M For Dry Eye Treatment
San Francisco-based Oyster Point Pharmaceuticals, a startup developing therapies for treating "dry eye" and other ocular diseases, said this week that it has raised $22M in a funding round. The funding was led by Versant Ventures and New Enterprise Associates (NEA). The company said funds will go to fund its efforts through Phase II clinical trials. Oyster Point's President and CEO is Jeffrey Nau.
posted on Thursday, November 9, 2017
Related companies:
Oyster Capital Partners
Related stories:
> Zosano Pharma Raises $30M
> Circle Pharma Ups Funding To $6.5M
> Zosano Pharma Raises $45M
> Zosano Pharma Expected To IPO Next Week
> ROXRO PHARMA Gets $42.7M
silicontap.com Home